Skip to main content

Dr. Ryan Moy, M.D., PH.D.

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
13
In the NPI registry since
2015
Medicare patients seen, 2024
108

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2015Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    NY license 287759
  • Internal Medicine Physician
    NY license 287759
  • Student in an Organized Health Care Education/Training Program

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
108
Services billed
471
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes9922
Established patient office or other outpatient visit, 30-39 minutes8830
Established patient office or other outpatient visit, 40-54 minutes4123
Established patient office or other outpatient visit, 20-29 minutes3822
New patient office or other outpatient visit, 60-74 minutes1717

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 7 companies reported 19 payments worth $14,666 in total to this clinician.

By type
Consulting Fee$12,581
Travel and Lodging$1,067
Food and Beverage$1,018

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jan 27, 2025E.r. Squibb & Sons, L.l.c.
Jan 27, 2025
Consulting Fee$7,740
Oct 8, 2025Gilead Sciences, Inc.
Oct 8, 2025
Consulting Fee
Company’s description;4278099;VEM US;12675814
$2,180
Sep 24, 2025Beone Medicines USA, Inc.
Sep 24, 2025
Consulting Fee
TEVIMBRA · Oncology
$1,950
Mar 2, 2025Novartis Pharmaceuticals Corporation
Mar 2, 2025
Travel and Lodging
travel to Miami, FL
$585
Jan 22, 2025Novartis Pharmaceuticals Corporation
Jan 22, 2025
Travel and Lodging
travel to Miami, FL · in-kind
$482
May 6, 2025Amgen Inc.
May 6, 2025
Consulting Fee$368
Aug 12, 2025Amgen Inc.
Aug 12, 2025
Consulting Fee$343

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $744,096 in research payments for these studies, mostly to the institutions running them.

  • LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor
    Novartis Pharmaceuticals Corporation
  • A phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or g…
    AstraZeneca Pharmaceuticals LP
  • A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors
    E.r. Squibb & Sons, L.l.c.
  • A phase 1/2, first-in-human, open label, dose escalation study of MVC-101, an egfr x CD3 conditional bispecific redirected activation (cobratm) protein in patients with unresectable locally advanced or metastatic cancer
    Takeda Pharmaceuticals U.S.A., Inc.
  • A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry and Preliminary Activity of [177Lu]Lu-FF58 in Patients With Selected Advanced Solid Tumors
    Novartis Pharmaceuticals Corporation
  • A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With or Without Pembrolizumab MK-3475 and,or Chemotherapy in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1,PD-…
    Merck Sharp & Dohme LLC
  • A Phase 1,2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab MK-3475 and Chemotherapy in Participants with 1L Locally Advanced Unresectable,Metastatic Gastroesophageal Adenocarci…
    Merck Sharp & Dohme LLC
  • A Phase 1,2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of Investigational Agents in Combination With Standard of Care Treatments as the Second-Line Treatment of Participants with Ad…
    Merck Sharp & Dohme LLC
  • An Open-label Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus (rNDV) Encoding Interleukin-12 (IL-12…
    AstraZeneca Pharmaceuticals LP
  • Morpheus NeoAdj HCC
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in New York

Sources

NPI registry (CMS NPPES, November 2026; record last updated May 3, 2021), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1164816005. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.